within Pharmacolibrary.Drugs.ATC.A;

model A01AB04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0029,
    k12             = 1.1,
    k21             = 1.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A01AB04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amphotericin B is a polyene antifungal agent primarily used for the treatment of serious systemic fungal infections, including aspergillosis, cryptococcosis, histoplasmosis, and candidiasis. It is generally reserved for severe cases due to its toxicity. Amphotericin B is approved for medical use and remains in clinical use, mainly as intravenous administration in hospital settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with systemic fungal infections, following intravenous administration.</p><h4>References</h4><ol><li><p>Hamill, RJ (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. <i>Drugs</i> 73(9) 919–934. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0069-4&quot;>10.1007/s40265-013-0069-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23729001/&quot;>https://pubmed.ncbi.nlm.nih.gov/23729001</a></p></li><li><p>Abdollahizad, E, et al., &amp; Rezaee, E (2023). Amphotericin B Pharmacokinetics: Inter-strain Differences in Rats Following Intravenous Administration of the Most Commonly Marketed Formulations of the Drug. <i>Iranian journal of pharmaceutical research : IJPR</i> 22(1) e134772–None. DOI:<a href=&quot;https://doi.org/10.5812/ijpr-134772&quot;>10.5812/ijpr-134772</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38116555/&quot;>https://pubmed.ncbi.nlm.nih.gov/38116555</a></p></li><li><p>Fisher, JF, et al., &amp; Newman, CA (2011). Candida urinary tract infections--treatment. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 52 Suppl 6 S457–S466. DOI:<a href=&quot;https://doi.org/10.1093/cid/cir112&quot;>10.1093/cid/cir112</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21498839/&quot;>https://pubmed.ncbi.nlm.nih.gov/21498839</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A01AB04;
